Jefferies cuts target for RxSight stock to USD 5.75

Published on 10/05/2026 at 06:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The target for RxSight stock was USD 5.75 on September 22, 2026. Q2 2026 revenue reached USD 33.74 million versus USD 32.55 million consensus.

RXST, US78349D1072, Illustration mit AI erstellt.

Jefferies cut its RxSight stock target from USD 6.50 to USD 5.75 and kept a Hold rating in a note dated September 22, 2026, according to MarketBeat. The move puts execution of RxSight's commercial reset at the center of the investment case.

Revenue beat, losses continue

RxSight generated USD 33.74 million of revenue in the second quarter of 2026, compared with USD 32.55 million consensus, according to MarketBeat. The company also posted an adjusted loss of USD 0.29 per share against a USD 0.33 consensus loss, a USD 0.04 improvement versus expectations.

The standardized financial statements show second-quarter 2026 net revenue of USD 33.741 million and a net loss attributable to common shareholders of USD 12.097 million. Operating cash flow was negative USD 9.538 million in the same period, keeping profitability and cash discipline central to the story.

Alcon deal raises strategic stakes

At the September 9, 2026 Wells Fargo Healthcare Conference, RxSight described a commercial plan built around deeper use of its Light Adjustable Lens among nearly 3,000 existing surgeon users. Investing.com reported that the company plans to double its US sales force through resource reallocation.

The July Alcon collaboration adds USD 200.0 million in upfront payments and a 30.00 percent royalty on future sales, according to Investing.com. Management said Alcon controls more than 50.00 percent of the presbyopic and PC-IOL market, giving RxSight a larger commercial channel if the collaboration reaches commercialization.

Nasdaq range keeps risk visible

RxSight was last quoted at USD 4.66 on Nasdaq on September 25, 2026, with a 52-week range of USD 4.48 to USD 13.22 and a market capitalization of USD 193.8 million. The stock's position near its yearly low contrasts with the USD 5.75 Jefferies target and the USD 8.17 consensus target reported by MarketBeat.

Execution decides the next phase

RxSight's investor-relations materials describe a commercial-stage medical technology company built around the Light Adjustable Lens system and Light Delivery Device. The central question is whether stronger use among existing surgeons can turn clinical differentiation into recurring revenue growth while the Alcon relationship develops.